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Abstract
Clinical drug trials are often conducted in selective patient populations, with relatively small numbers of patients,
and a short duration of follow-up. Observational studies are therefore important for collecting additional
information on adverse drug events (ADEs). Currently, there is no guidance regarding the methodology for
measuring ADEs in such studies. Our aim was to evaluate whether the methodology used to assess non-serious
ADEs in observational studies is adequate for detecting these ADEs, and for addressing limitations from clinical
trials in patients with type 2 diabetes mellitus. We systematically searched MEDLINE and EMBASE for observational
studies reporting non-serious ADEs (1999-2008). Methods to assess ADEs were classified as: 1) medical record
review; 2) surveillance by health care professionals (HCP); 3) patient survey; 4) administrative data; 5) laboratory/
clinical values; 6) not specified. We compared the range of ADEs identified, number and selection of patients
included, and duration of follow-up. Out of 10,125 publications, 68 studies met our inclusion criteria. The most
common methods were based on laboratory/clinical values (n = 25) and medical record review (n = 18). Solicited
surveillance by HCP (n = 17) revealed the largest diversity of ADEs. Patient surveys (n = 15) focused mostly on
hypoglycaemia and gastrointestinal ADEs, laboratory values based studies on hepatic and metabolic ADEs, and
administrative database studies (n = 5) on cardiovascular ADEs. Four studies presented ADEs that were identified
with the use of more than one method. The patient population was restricted to a lower risk population in 19% of
the studies. Less than one third of the studies exceeded pre-approval regulatory requirements for sample size and
duration of follow-up. We conclude that the current assessment of ADEs is hampered by the choice of methods.
Many observational studies rely on methods that are inadequate for identifying all possible ADEs. Patient-reported
outcomes and combinations of methods are underutilized. Furthermore, while observational studies often include
unselective patient populations, many do not adequately address other limitations of pre-approval trials. This
implies that these studies will not provide sufficient information about ADEs to clinicians and patients. Better
protocols are needed on how to assess adverse drug events not only in clinical trials but also in observational
studies.
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Introduction
Medication safety assessment during the pre-approval
regulatory phase is known to have limitations. Pre-
approval clinical trials are often conducted in selective
patient populations, with relatively small numbers of
patients, and a short duration of follow-up [1,2]. Because
of these limitations, several systems have been developed
to monitor drug safety after marketing, including spon-
taneous reporting systems and risk management plans.
Such safety assessment focuses primarily on detection of
serious adverse drug events (ADEs) [3]. Little attention
is given to the assessment of symptomatic or non-life-
threatening ADEs, while the proportion of such ADEs is
relatively common [4,5]. Symptomatic ADEs may affect
patients’ q u a l i t yo fl i f ea n da d h e r e n c et ot r e a t m e n t ,a n d
thereby the risk-benefit ratio of a drug.
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important to get more information on ADEs occurring
in patient populations actually using the drugs [2,6,7].
This additional value, however, will only be achieved
when the methodology used in such studies allows for
adequate capturing of non-serious ADEs in an unrest-
ricted population. The use of different methods for
assessing ADEs, such as spontaneous and solicited
reporting, medical record review, and patient surveys,
may lead to differences in observed ADEs [8,9]. No gui-
dance exists regarding the methods to be used for mea-
suring ADEs in post-marketing studies [10-13].
Our aim was to evaluate the current methodology for
assessing non-serious ADEs in observational studies,
using oral antihyperglycemic drugs (OAD) as case.
Research questions addressed are: (1) which methods of
ADE assessment are used, (2) what is the range of non-
serious ADEs captured for each method, (3) do the
observational studies address known limitations of pre-
approval trials regarding patient population and follow-
up.
Methods
Search Strategy
We conducted a systematic search of MEDLINE and
EMBASE for observational studies reporting on ADEs in
patients with diabetes, and published between January 1
1999 and January 1 2009. We searched for papers using
MeSH headings, subheadings and free-text terms related
to the following domains: (1) “adverse events”,a n d( 2 )
“observational study design”,a n d( 3 )“drug treatment”
combined with “diabetes” (see Additional file 1 for
detailed description of the search strategy). Using the
boolean operator ‘AND’, only papers satisfying all three
domains were included.
Study Selection
Observational studies, i.e. non-experimental studies
where decisions regarding the prescription of drugs to
each patient were made by their health care provider in
every-day clinical practice, were included when they
reported rates of non-serious ADEs in adult patients
with type 2 diabetes mellitus treated with OAD. We
excluded open-label extensions of clinical trials. Non-
serious ADEs were defined as any unfavourable and
unintended sign (including abnormal laboratory values)
or symptom or disease that may present during treat-
ment with a pharmaceutical product and which was not
life-threatening, requiring hospitalization or resulted in
significant disability or death.
The first title and abstract screening was done by LH,
excluding editorials, comments, notes, letters, rando-
mized clinical trials (RCTs), case reports, and studies
not including patients with diabetes or not including
OAD (see also Figure 1 for exclusions). PD screened a
10% sample which showed that LH had not excluded
any potentially relevant studies. Screening of the
remaining abstracts and full-texts was done by two
reviewers independently. We restricted our selection to
studies published in English, German, French, Spanish
or Dutch language.
Data Extraction
Information was collected from the selected publications
each by two reviewers (PD/LH, DD/LH or FHR/LH)
using a standardized data extraction form. Data were
extracted regarding methods used for assessing ADEs,
the ADEs identified, inclusiona n de x c l u s i o nc r i t e r i ao f
patient population, sample size, and duration of follow-
up. In addition, we extracted data on study design and
medications covered. Discrepancies in data extraction
occurred in 3 cases regarding ‘methods used for asses-
sing ADEs’, in 8 cases regarding ‘sample size’,a n d9
cases regarding ‘duration of follow-up’. These discrepan-
cies were often the result of unclear descriptions in the
publications, and were solved by consensus based on a
joint re-evaluation of what was described in the
publication.
Methods for ADE assessment
ADE assessment in observational studies can be based
on review of existing practice-based data, such as medi-
cal records, laboratory reports, and administrative data,
on surveillance by health care professionals (HCP) or on
survey of patients [9,10,14]. Following this distinction,
we defined the employed methods as: 1) medical record
review, i.e. possible ADEs were collected from documen-
tation or reports made by HCP in existing medical
records; 2) solicited surveillance by HCP, i.e. requesting
HCP to report possible ADEs either on Case Report
Forms (prospective) or on socalled Prescription Event
Monitoring forms (retrospective) [7]; 3) patient survey,
including the use of open or closed patient question-
naires, checklists or diaries; 4) administrative data, mak-
ing use of diagnostic codes related to possible ADEs in
administrative or claims data; 5) laboratory or clinical
values indicating ADEs, including results of laboratory
measurements and physical examinations such as weight
or blood pressure; 6) non-specified methods. Reported
ADEs were categorized on anatomy or pathophysiology
level according to Common Terminology Criteria for
Adverse Events (CTCAE v3.0) classification [15].
Patient population
Based on the reported patient inclusion and exclusion
criteria, we classified studies as: (A) restricting the
patient population to lower risk patients, (B) restricting
to higher risk patients, (C) applying restrictions needed
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ing patients with a condition or medication use at base-
line which would confound the outcome, (D) no
restrictions reported.
Sample size and duration of follow-up
We assessed the number of patients exposed to OAD, as
well as the duration of their follow-up. For studies
including more than one treatment group, we consid-
ered the sample size of the largest group exposed to
OAD treatment. For studies including a diabetic subco-
hort, the overall number of exposed patients was consid-
ered as the sample size. Based on recommendations
from regulatory agencies for safety assessment
[11,12,16,17], we categorized sample sizes into six levels:
1) < 100 patients; 2) 100 to 299 patients; 3) 300 to 599
patients; 4) 600 to 1499 patients; 5) 1500 to 5000 and 6)
> 5000 patients. Duration of follow-up for cohort stu-
dies was classified into: 1) ≤6 months; 2) 7-12 months;
3) 13 to 24 months; 4) more than 2 years.
Data Analysis
Some publications reported on multiple studies with dif-
ferent patient populations and methods. We conducted
analysis at this study level. We present the type, median
number and interquartile range (IQR) of ADEs at cate-
gory level reported for the six different methods of ADE
assessment. Sample size and duration of follow-up are
also compared for the different ADE assessment meth-
ods. We calculated the number of studies reaching regu-
latory recommendations for pre-approval safety
assessment of drugs intended for long-term treatment of
non-life-threatening conditions, i.e. 100 patients exposed
for a minimum of 1 year or 300-600 patients for 6
months can be adequate to assess the pattern of ADEs
over time [11,12].
Results
The search resulted in 10,125 articles, out of which we
selected 904 articles for full-text screening (Figure 1),
resulting in 64 relevant articles reporting on 68 studies
Total citations found 
10,125
Identified from: 
MEDLINE: 3,584
EMBASE: 6, 541
Full-text review 
n=904
Excluded
(based on title and 
abstract review) 
n=9,221
Reasons for exclusion:
- No original studies 
(editorials, comments, 
notes, letters)  
- RCTs, case reports and 
case series 
- Not in diabetes patients 
- Not with oral 
antihyperglycemic drugs
Final set for data 
extraction
n=64 including
68 studies 
Excluded
n=840 Reasons for exclusion:
- No type 2 diabetes 
mellitus (sub) population 
- No rates reported on 
non-serious ADEs 
- Languages: Polish 
(n=5); Japanese (n=1), 
Norwegian (n=1) 
- No report of original 
study (systematic reviews, 
meta-analysis) 
- No observational study
Figure 1 Study flow diagram.
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studies).
Methods of ADE assessment
The most commonly employed methods for assessing
ADEs were based on laboratory/clinical values (n = 25),
medical record review (n = 18), and solicited surveil-
lance by HCP (n = 17) (Table 1). Surveillance by HCP
was conducted prospectively using Case Report Forms
in 12 studies, and retrospectively in 5 Prescription Event
Monitoring studies. Among the 15 studies which used
patient survey methods, 10 studies used a closed ques-
tionnaire, including two validated questionnaires [18,19],
one used a checklist [20], one used a semi-structured
interview guide where patients could report any per-
ceived ADEs [21], and one used a 16-item content-vali-
dated questionnaire, containing closed and open-ended
questions focusing among other issues on specific
adverse events [22]. A patient diary was used in two stu-
dies [23,24]. Administrative databases were used in 5
studies, and in 7 studies, the data collection method was
not fully specified.
ADEs identified with different methods
The largest range of ADEs was identified with solicited
surveillance by HCP, yielding a median of 4 ADE cate-
gories (Table 1). The range was even higher for retro-
spective surveillance (median 7, IQR 4-9) in comparison
to prospective surveillance (median 3.5, IQR 2-6). Medi-
cal record review identified a median of 2 ADE cate-
gories (Table 1), covering many different areas (Table
2). Other specified methods assessed mostly 1 ADE
category per study. Patient survey methods often
focused on perceived hypoglycaemia or gastrointestinal
ADEs (Table 2). Administrative databases were mainly
used for cardiac ADEs, and laboratory/clinical values
often included hepatic or metabolic problems or weight
increase (Table 2). Four studies identified the same
ADE, either hypoglycaemia or hepatic dysfunction, using
more than one method, in particular a combination of
laboratory values and other methods [25-28].
Patient population
In 28 studies (41%), there were no specific limitations
regarding the patient population included. In two studies
(3%), no inclusion or exclusion criteria were specified
[29,30]. Thirteen studies (19%) limited inclusion of
patients to lower risk patients (category A) by including
only patients with less severe diabetes [20,26,27,31-33] or
patients on monotherapy [19,24,27,33-36], or OAD-naïve
patients [27,35] or by excluding high risk patients who
failed previous therapy [37] or with multiple comorbidity
[20,38,39]. Fifteen studies (22%) limited the inclusion to
more complicated cases (category B), such as inadequately
controlled by or not tolerating previous medication
[40-45], receiving combination treatment [46-48] or insu-
lin [21,23,45,49] or treated with maximum dose of medica-
tion [50]. Furthermore, 18 studies (27%) excluded patients
based on the presence at baseline of the outcome or a con-
dition that could influence the outcome
[18,24,25,33,37-39,47,51-55], non-availability of measure-
ments and/or clinical visits [35,37,46,47,50,54,56,57],
inability to fill in questionnaires (category C) [18,21,46,56].
Sample size and duration of follow-up
Studies using patient survey methods, medical record
review, or laboratory data often included less than 300
patients (Figure 2). A sample size of equal or more than
1500 was achieved by all studies using administrative data-
bases, and in many studies using solicited surveillance by
HCP. Overall, the follow-up period did not exceed one
year in 77% of the cohort studies. Longer follow-up peri-
ods were mostly seen in studies using administrative data
or laboratory/clinical values. Evaluation of sample size and
follow-up jointly showed that all 3 cohort studies using
administrative data exceeded the requirements of the
guidelines for pre-approval safety assessment, whereas this
was the case in less than a quarter of the studies using any
of the other specified methods (Table 3).
Discussion
Commonly used methods for assessing non-serious
ADEs in patients with diabetes were based laboratory or
Table 1 Median number and interquartile range (IQR) of different ADE categories identified for studies using different
assessment methods
Number of studies* median number of ADE categories (IQR) References
Method of ADE assessment
Medical record review 18 2 (1-3) [22,25,34,35,38,40,41,49-52,78-83]
Surveillance by HCP 17 4 (2-7) [23,29,30,42,43,84-95]
Patient survey 15 1 (1-2) [18-24,26,31,40,44,46,53,56]
Administrative data 5 1 (1-1) [33,47,54,96,97]
Laboratory/clinical values 25 1 (1-2) [25-28,32,35-37,39-41,44,45,50,55,57,80-83,98-101]
Non-specified 7 2 (1-10) [27,28,36,48,99-101]
* Total exceeds 68 since one study may use several methods
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veillance by HCP. The latter method identified the
broadest range of ADE categories. Patient survey meth-
ods were used in 22% of the studies, and often focused
on a limited range of ADEs, such as hypoglycaemia or
gastrointestinal ADEs. The patient population was
restricted to a lower risk population in a fifth of the stu-
dies. Less than one-third of studies exceeded pre-
approval requirements regarding sample size and dura-
tion of follow-up.
Solicited surveillance by health care providers, using
either prospective or retrospective data collection,
revealed the largest diversity of ADEs, indicating that
doctors register more events on such forms than in rou-
tine medical records. This is in line with previous find-
ings that medical record review, although broadly used
for assessing ADEs, results in incomplete findings
[11,58]. Since there is no systematic documentation of
ADEs in medical records, partly due to limitations of
the documentation systems [59,60], review of such
records lacks a standardized and reliable method to
search for ADEs [61]. For non-serious, symptomatic
ADEs the incomplete documentation of adverse events
in medical records is even more the case when such
ADEs do not warrant immediate action [1,62]. Prescrip-
tion Event Monitoring studies, which make use of an
open question to report all events that occurred during
drug use on special forms, or prospective studies using
prespecified Case Report Forms may solve this problem.
Patient reports can be of great value for ADE assess-
ment because of the differences between reports from
patients and health care providers [4,63-66]. Patients are
Table 2 Types of ADEs reported at category level for studies using different assessment methods (number of studies
presented in table)
Adverse events at CTCAE category
level
Medicalrecord
review
HCP surveill-
ance
Patient
survey
Admini-strative
data
Lab/clinical
values
Non
specified
Gastrointestinal 9 14 3 5
Neurology 3 6 1 3
Cardiac General 9 9 4 1 4
Blood/Bone Marrow 2 4 5 1
Pulmonary/Upper Respiratory 1 2 2
Hepatobiliary/Pancreas 3 7 1 11 2
Auditory/Ear 1 1
Ocular/Visual 1
Dermatology/Skin 1 4 3
Musculoskelal/Soft Tissue 1 1
Renal/Genitourinary 1 1 2 2
Constitutional symptoms:
- weight 6 12
- other 1 3 1
Pain 3 7 2
Endocrine 1
Infection 1 3
Allergy/Immunology 1
Sexual/Reproductive Function 1
Metabolic:
- hypoglycaemia 7 7 8 3 5
- other 4 1 7 1
General ADEs/Tolerability* 3 12 3 3 5
CTCAE Common Terminology Criteria for Adverse Events v3.0; * not categorized
0
2
4
6
8
10
12
Medical
record
HCP
surveillance
Patient
survey
Admininstra-
tive data
Lab/clinical
values
Non-
specified
n
u
m
b
e
r
 
o
f
 
s
t
u
d
i
e
s
<100 100-299 300-599 600-1499 1500-5000 >5000 patients
Figure 2 Sample size included in studies using different
assessment methods.
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matic ADEs, such as dizziness, malaise, fatigue, sexual
function disorders, and pain [67-69]. Surprisingly, we
f o u n dt h a tp a t i e n ts u r v e ym e t h o d sw e r eu s e di nar e l a -
tively small number of studies, and moreover, often lim-
ited in their focus. Although comprehensive
questionnaires have been developed to assess patient-
perceived ADEs [70,71], such questionnaires were not
used in observational studies for diabetes treatment.
Laboratory values may have a limited value for asses-
sing non-serious ADEs, since mainly hepatic and meta-
bolic problems were identified by these methods. This is
in contrast with previous estimates that more than half
of the ADEs can be detected by biochemical tests [72].
Administrative databases are also limited regarding the
types of ADEs that can be identified. Such databases can
be useful for assessing ADEs leading to hospitalization
but have less value for assessing non-serious ADEs.
Diagnostic administrative coding is likely to be both
incomplete and unspecific for detecting non-serious
ADEs [73], because these ADEs do not always call for a
documented action from the health care provider [1,62].
Currently, European Medicines Agency regulators work
on strengthening this source of information by establish-
ing a European Network of Centres for Pharmacovigi-
lance and Pharmacoepidemiology [74].
Combining methods for ADE assessment could
address some limitations seen with all methods leading
to under- or overreporting. ADEs which are likely to be
underreported because of improper registration or cod-
ing in medical records might be complemented by
laboratory values [73]. The same applies to doctor and
patient reports that may complement each other [75]. In
our review, however, only a four studies identified the
same ADE using a combination of methods.
Observational post-marketing studies can provide
additional information on ADEs when sufficient num-
bers of patients are being followed in daily practice,
including those with higher risks, more comorbidity,
concomitant drugs, and longer disease duration. The
majority of studies in our review included such patient
populations, thus adding valuable information on ADEs
in patient groups underrepresented in pre-approval
trials. The number of patients included and the duration
of follow-up, however, showed similar limitations as
pre-registration trials, and the majority of studies did
not go beyond the pre-approval recommendations for
safety assessment of diabetes medication. Because of
workload, long follow-up for large numbers of patients
can be problematic in studies where the patients or the
health care providers need to provide the information. It
is less problematic when data can be collected from
existing databases.
Our study has some limitations. It has previously been
recognized that searching the literature for studies
reporting on drug safety is difficult [76,77], and also
indexing of observational studies may not be as robust
as of RCTs. We therefore used a broad search strategy
to identify possibly relevant studies. Second, the results
are based on studies conducted in diabetes patients
using OADs. For other therapeutic areas and other
drugs, results may be different. Third, we used the
CTCAE v3.0 classification to define ranges of ADEs
identified by different methods. Although the CTCAE
categories are quite similar to the primary system organ
classes in the MedDRA hierarchy, minor differences in
ranges may occur when using this alternative classifica-
tion system. Finally, we encountered several problems
regarding unclear or incomplete reporting. Although it
was not our aim to evaluate studies on the quality of
reporting, and we did not exclude studies on these
grounds, we observed that information on, for example,
exclusion criteria and response rates was often lacking.
Conclusion
The current set up of ADE assessment in post-market-
ing studies is not adequate for countering limitations
acknowledged in pre-approval trials. The assessment of
non-serious ADEs is limited by the choice of methods.
Many observational studies rely on methods that are
Table 3 Number of cohort studies for each assessment method where sample size and follow-up period exceed
regulatory recommendations for pre-approval safety assessment
Regulatory recommendations [11,12]
Method of ADE assessment Total number of cohort studies > 100 patients > 12 months > 300 patients > 6 months
Medical record review 17 0 4
Surveillance by HCP 17 0 4
Patient survey 6 0 1
Administrative data 3 0 3
Laboratory/clinical values 22 3 3
Non-specified 7 2 1
Total 71 5 17
* Total exceeds 68 since one study may use several methods
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vey methods are underutilized, and there is a lack of
studies that try to combine different methods to assess
ADEs. This implies that these studies will not provide
sufficient information about ADEs to clinicians and
patients. Better protocols are needed on how to assess
adverse drug events not only in clinical trials but also in
observational studies.
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the domains, terms and boolean operators used in the systematic search
of Medline and Embase for observational studies reporting on ADEs in
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